# Radioimmunotherapy With 131I-L19SIP in Patients With Cancer

> **NCT01242943** · PHASE1,PHASE2 · TERMINATED · sponsor: **Philogen S.p.A.** · enrollment: 34 (actual)

## Conditions studied

- Patients With Cancer

## Interventions

- **DRUG:** 131I-L19SIP Radioimmunotherapy (RIT)

## Key facts

- **NCT ID:** NCT01242943
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2011-02
- **Final completion:** 2011-05
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** With the determination of the RD and a well established understanding of the safety and tolerability profile, the main endpoints of the study have been met.
- **Last updated:** 2011-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01242943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01242943, "Radioimmunotherapy With 131I-L19SIP in Patients With Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01242943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*